C-reactive protein as a potential predictive biomarker for kidney cancer

A recent study published in Science Direct describes how a change in blood C-reactive protein (CRP) levels during the early phase of nivolumab treatment for metastatic renal cell carcinoma (mRCC) may be used to predict survival among patients with mRCC. Read more in Science Direct here

read more

Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients

Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have revolutionised the treatment for metastatic renal cell carcinoma (RCC). However, the most appropriate duration for immunotherapy treatment is not clear. In a recent analysis of the results from the phase III CheckMate 214 trial, all RCC patients randomised to receive the nivolumab/ipilimumab combination had longer […]

read more

PARP inhibitors, vaccines and combination therapies for kidney cancer

In this interview with OncLive, professor Sumanta Kumar Pal from City of Hope Hospital in California discusses the potential of poly ADP ribose polymerase (PARP) inhibitors, chimeric antigen receptor (CAR)-based products, vaccines, and novel drug combinations for the treatment of metastatic renal cell carcinoma (mRCC). Results from the phase Ib/II TiNivo study of the combination […]

read more

Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more

IKCS 2019: Biomarkers in kidney cancer

In this interview taken from the International Kidney Cancer Symposium (IKCS) 2019 held in Miami, USA earlier this month, Dr Tian Zhang, from Duke University talks about existing and emerging immunotherapy biomarkers for kidney cancer, and the PEDIGREE study. Dr Zhang talks about PBRM1, PD-L1, and tumour mutational burden as prognostic biomarkers, and angiogenesis, CD8-infiltrating […]

read more

Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone

A recent phase II clinical trial has shown that combined use of a PD-1 inhibitor and a PD-L1 inhibitor proved no more beneficial than anti-PD-1 treatment alone in metastatic renal cell carcinoma (RCC) patients who had already been treated with targeted therapy. There was no significant difference in the primary endpoint of the study, which […]

read more

Deciding on the ideal first-line treatment for rare and advanced kidney cancer

Currently, doctors are unsure which is the best first-line treatment for patients with rare and advanced kidney cancers. During a debate at the 18th International Kidney Cancer Symposium (IKCS), 5 doctors discussed their opinions. During the debate, the use of immunotherapy versus targeted kinase inhibitors (TKI) for the first-line treatment of advanced non-clear cell renal […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

Promising early studies with pegilodecakin plus immunotherapy in pretreated kidney cancer

A recent phase 1b clinical trial investigated the use of pegilodecakin in combination with anti-PD-1 monoclonal antibodies nivolumab or pembrolizumab. The combination showed a “favourable” response in patients with non-small cell lung cancer and kidney cancer. Pegilodecakin works by stimulating the survival, proliferation and “killing” potential of CD8+ T cells, which can recognise and destroy […]

read more

ESMO 2019: ADAPTeR study to evaluate the role of nivolumab before and after surgery – results of biomarker analysis

Results from the ADAPTeR study to evaluate the role of anti-PD1 checkpoint inhibitors before and after surgery in patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. ADAPTeR is a single centre study in which metastatic RCC patients were treated with […]

read more
Showing 1 to 10 of 100 results
  TOP